Nanotechnology in Infantile Hemangioma Management.

Abstract

Infantile hemangioma (IH) is the most prevalent benign vascular tumor among infants. While most hemangioma cases typically undergo spontaneous resolution, there is a risk of complications and concern over changes in appearance in certain circumstances. The treatment options include oral and topical drug therapy, laser therapy, and surgery. Because the lesions are (but not exclusively) formed on the skin's surface and exhibit features typical of tumors, there are opportunities for implementing nanoparticle technology for systemic and topical treatments. Nanotechnology in drug delivery generally aims to boost the efficacy of substance penetration or absorption, prevent systemic side effects by passive or active targeting, prolong effectiveness, and reduce the dose and duration of treatment. Several types of nanoparticles have been selected as research subjects in nanoparticle-based studies for treating IH. The type of nanoparticle is chosen based on evaluations of many factors, such as the active substance's physical and chemical compatibility, target site, and route of administration, and the formula is constructed by using an optimization process, resulting in a system with distinctive advantages.